REGENXBIO stock: Bank of America sets USD 15.00 target for REGENXBIO stock

Published on 10/24/2026 at 04:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 108.02 million versus USD 21.36 million a year earlier. REGENXBIO stock targets fourth-quarter data.

Analyst targets and clinical dates

Bank of America set a USD 15.00 target on October 21, 2026.
Second-quarter revenue reached USD 108.02 million, versus USD 21.36 million a year earlier.
Topline pivotal data for sura-vec are anticipated in the fourth quarter of 2026.

RGNX, US75901B1070, Illustration mit AI erstellt.

REGENXBIO (ISIN US75901B1070) received a USD 15.00 price target from Bank of America Securities on October 21, 2026, while the analyst maintained a Buy rating. Markets Insider reported the call as REGENXBIO moves toward pivotal wet AMD data.

Targets reflect a divided view

The latest target sits alongside a USD 22.00 Outperform target that Mizuho initiated on October 5, 2026. Markets Insider carried the Mizuho view, while the October 21 Bank of America target was USD 7.00 lower.

REGENXBIO reported USD 108.02 million in second-quarter 2026 revenue, compared with USD 21.36 million in the second quarter of 2025. The company also reported USD 22.71 million in net income for the second quarter of 2026, versus a GAAP net loss of USD 70.87 million a year earlier, according to Markets Insider.

Three recent milestones

On October 5, 2026, Mizuho initiated coverage with a USD 22.00 target. On October 12, 2026, REGENXBIO announced an October 20 investor event for surabgene lomparvovec, or sura-vec, in wet age-related macular degeneration. On October 21, 2026, Bank of America Securities set its USD 15.00 target and maintained a Buy rating.

What dates shape the outlook?

The company anticipated topline pivotal data for sura-vec in the fourth quarter of 2026 in its October 12 release. REGENXBIO said the program covers the ATMOSPHERE and ASCENT pivotal trials. The next estimated earnings date is November 5, 2026, according to Yahoo Finance.

Price remains below targets

REGENXBIO was last at USD 6.68 on Nasdaq on October 23, 2026 at 4:00 p.m. ET. That level was 55.47 percent below Bank of America's USD 15.00 target and sat within the USD 5.46 to USD 16.19 52-week range. The market capitalization was USD 441.0 million as of October 23, 2026. The further course of trading is shown by the continuously updated real-time quote of REGENXBIO stock.